Berberine a ‘multipotent’ therapy for reducing risk of Alzheimer’s disease
Researchers from Hong Kong and Macau conducted a systematic review to evaluate the neuroprotective effects of berberine. Their article was published in the journal BMC Complementary and Alternative Medicine.
- Alzheimer’s disease (AD) is a complex disease driven by multiple factors.
- Therapeutic strategies based on decreasing the amount of B-amyloid in the brain have failed in clinical trials, suggesting that AD therapy should not be focused on addressing a single cause, but rather a number of different pathways that lead to the disease.
- Berberine, an alkaloid derived from various Berberis species, is widely used in East Asia to treat a wide range of health problems.
- Recently, studies have reported that berberine has neuroprotective effects on AD animal models.
- However, no clinical trial has been carried out to test these effects.
- For their pre-clinical trial review, the researchers searched five online databases for publications reporting effect of berberine treatment on animal models of AD.
- They found 15 papers published no later than March 18 that fit their criteria.
- After analyzing data from those studies, the researchers reported that in multiple animal models with memory defects, berberine showed significant memory-improving activities.
- These activities were mediated by different properties, including anti-inflammatory, antioxidant, cholinesterase-inhibiting and anti-amyloid activities.
Based on their findings, the researchers concluded that berberine is a promising multi-potent agent against Alzheimer’s disease.
Read the full study at this link.
Yuan NN, Cai CZ, Wu MY, Su HX, Li M, Lu JH. NEUROPROTECTIVE EFFECTS OF BERBERINE IN ANIMAL MODELS OF ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW OF PRE-CLINICAL STUDIES. BMC Complementary and Alternative Medicine. 23 May 2019;19(1). DOI: 10.1186/s12906-019-2510-z
For full references please use source link below.